Immunotherapy for pediatric cancer.
Immunotherapy for pediatric cancer.
复制标题
小儿癌症的免疫治疗。
DOI：
10.1016/j.bbmt.2007.10.014
复制
发表时间：
2008
期刊：
影响因子：
--
通讯作者：
Cooper,LaurenceJN
中科院分区：
文献类型：
--
作者：
Grupp,StephanA;Verneris,Michael;Sondel,PaulM;Cooper,LaurenceJN
通过行为改变和采用筛查计划可以提高成人癌症的生存率。然而，这些方法不能轻易应用于降低儿童癌症的发病率和死亡率。相反，儿科肿瘤学家必须依靠手术和疗法来治疗而不是预防恶性肿瘤。化疗、放疗和手术的系统应用显着提高了生存率，但这些改善是有代价的。儿童通常接受几十年前设计的化疗药物，这些药物具有可预测的副作用，导致长期幸存者丧失潜力。基于免疫疗法的靶向应用的出现为癌症儿童提供了一种新型溶瘤疗法，可用于治疗传统方法难治的疾病，并在不影响缓解的情况下减轻当前治疗方案的毒性。这篇综述探讨了免疫系统的 3 个组成部分——T 细胞、自然杀伤 (NK) 细胞和抗体——如何用于治疗儿科恶性肿瘤。
Improvements in adult cancer survivorship can be achieved from behavioral changes and adopting screening programs. Yet, these approaches cannot be readily applied to lower the morbidity and mortality from childhood cancers. Rather, pediatric oncologists must rely on procedures and therapies to treat, rather than prevent malignancies. The systematic application of chemotherapy, radiation therapy, and surgery has led to remarkable advances in survival but these improvements have come at a cost. Children routinely receive chemotherapy agents that were designed decades ago, and these drugs have predictable side effects that result in the loss of potential for long-term survivors. The advent of targeted applications of immune-based therapies offers children with cancer a new class of oncolytic therapies that may be used to treat disease refractory to conventional approaches and lessen the toxicity of current treatment regimens without compromising remission. This review explores how 3 components of the immune system—T cells, natural killer (NK) cells, and antibodies—can be used for therapy of pediatric malignancies.